earnings
confidence high
sentiment positive
materiality 0.78
Omnicell Q2 revenue $312M (+7% YoY); raises FY non-GAAP EPS and EBITDA guidance
OMNICELL, INC.
- GAAP net income $24M ($0.52 diluted EPS) vs $6M ($0.12) YoY; non-GAAP EPS $0.94 vs $0.45.
- Non-GAAP EBITDA $67M vs $38M YoY; received $15M in IEEPA tariff refunds.
- FY2026 guidance raised: non-GAAP EBITDA $175M-$185M, non-GAAP EPS $2.15-$2.30.
- Nnamdi Njoku promoted to President and COO effective July 1, 2026.
- Added Rick Couldry as SVP Chief Pharmacy & Clinical Officer and Dan Mandoli as SVP/GM Specialty Pharmacy.